Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals and the Institute for OneWorld Health (iOWH) have entered into a joint research agreement to discover antibacterial compounds for treating shigellosis, also known as bloody diarrhoea.
Subscribe to our email newsletter
OneWorld Health has received significant funding for this project from the Department for International Development (DfID) in the United Kingdom.
Anacor Pharmaceuticals CEO David Perry said the company has demonstrated that its boron-based chemistry platform and strength in antibacterial research has the potential to create new antibiotics.
"We hope to leverage these to address a disease that affects over one hundred million people annually," Perry said.